New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patientson November 20, 2019 at 5:37 am
Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 Months DURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (HTBX), presented additional positive ...
- ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein Formulationson November 20, 2019 at 3:30 am
ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 ...
- Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 90%?on November 19, 2019 at 5:31 pm
But really big losses can really drag down an overall portfolio. So consider, for a moment, the misfortune of Lattice Biologics Ltd. (CVE:LBL) investors who have held the stock for three years as it ...
- WuXi Biologics Congratulates Tychan on the World's First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteerson November 18, 2019 at 3:43 pm
SHANGHAI, Nov. 18, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, ...
- Retinal Drugs and Biologics Market – Global Sales, Ex-Factory Price, Revenue, Gross Margin Analysis 2026on November 18, 2019 at 7:27 am
Nov 18, 2019 (Global QYResearch via COMTEX) -- Ameco Research in its report titled, "Retinal Drugs and Biologics Market Analysis 2019 – Projections Report 2026," offers comprehensive insights and ...
- Heat Biologics EPS misses by $0.05on November 15, 2019 at 5:50 am
Heat Biologics (NASDAQ:HTBX): Q3 GAAP EPS of -$0.18 misses by $0.05. cash, cash equivalents and short-term investments of $15M ...
- Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Updateon November 15, 2019 at 4:30 am
November 15, 2019 (ACCESSWIRE via COMTEX) -- Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer Patients MORRISVILLE, NC / ACCESSWIRE / November 15, 2019 /Heat Biologics, ...
- Low clinical value in repeat latent tuberculosis tests in patients taking biologicson November 14, 2019 at 7:21 am
ATLANTA — Repeat, routine testing for latent tuberculosis infection among patients receiving biologics is both costly and of low clinical value, according to findings presented at the 2019 ACR/ARP ...
- Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMOon November 14, 2019 at 3:00 am
INCHEON, South Korea, Nov. 14, 2019 /PRNewswire/ -- Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security ...
- Does Response to Biologics Differ in Early- vs Late-Onset RA?on November 12, 2019 at 8:03 am
To determine whether differential safety or efficacy might justify withholding biologics from older patients, Jinno and colleagues analyzed data from a multicenter Japanese registry enrolling patients ...
via Bing News